

## CORRIGENDUM

# Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, K. Petrakova, K. L. Blackwell, E. P. Winer, W. Janni, S. Verma, P. Conte, C. L. Arteaga, D. A. Cameron, S. Mondal, F. Su, M. Miller, M. Elmeliogy, C. Germa & J. O'Shaughnessy

*Ann Oncol* 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155)

The following has been added to the 'Disclosure' section: "CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial)."